Sandoz has launched a generic paclitaxel formulation. It is the first generic of Abraxis BioScience’s (a Bristol Myers Squibb Co.) Abraxane to be approved by the Food and Drug Administration.

The data hint at sirolimus becoming a useful option or even a replacement for paclitaxel, but full 5-year follow-up is needed ...

First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be near-term ...

The arrival of DESs was seen as the third revolution in interventional cardiology, after balloon angioplasty and BMS. These initial ... agents such as sirolimus or paclitaxel.

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY.

On the buy write, if BMY closes above $56 at expiration on, you will be assigned and earn $2.55 per share on $53.45 per share at risk, or 4.77%. Over a holding period of 29 days, the annualized ...

PRINCETON, N.J., November 05, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024.

Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...